FOLH1 and pachyonychia congenita: PSMA and GRPR expression have been reported as complementary [69, 70], and as GRPR is particularly overexpressed in earlier stages of PC [18], GRPR-targeting radiopharmaceuticals may be more suitable in this specific clinical scenario.